Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar Continuous vs Routine Infusion in Advanced Squamous Cell Lung Cancer
NCT02283476Phase 3Unknown
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Nov 2014
- Primary completion
- Nov 2017
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of endostar in squamous cell carcinoma of the lung (LSCC), sponsored by Simcere Pharmaceutical Group. Status: unknown.
02
Drugs
endostar
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT02283476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02283476.